Trethera shares exciting progress in its research on optic neuritis and autoimmune diseases. After the FDA granted Orphan Drug designation for TRE-515 in optic neuritis and acute disseminated encephalomyelitis (ADEM), Trethera began building deeper connections with patient communities.
In this talk, Trethera leaders discuss:
- The scientific promise behind TRE-515 in rare autoimmune conditions
- FDA recognition through orphan drug status
- Insights into patient experiences and needs
- How patient partnerships shape the company’s development strategy
This presentation highlights the intersection of groundbreaking science and real-world patient impact.